$126,485,055

Department of Health and Human Services·Office of Assistant Secretary for Preparedness and Response

ACTION DATE2026-03-23·SOURCEUSASPENDING·SOURCE IDCONT_AWD_75A50123C00045_7505_-NONE-_-NONE-

Award description

ADVANCED RESEARCH AND DEVELOPMENT ACTIVITIES FOR NOVEL IMMUNOGENICITY ASSAYS AND SAMPLE COLLECTION TECHNOLOGIES AS PART OF BARDA?S CONTINUING SUPPORT FOR COVID-19 VACCINE DEVELOPMENT, ASSESSING IMPACT OF VARIANTS ON VACCINE IMMUNOGENICITY, AND ANALYZ

Verbatim from USAspending.gov. Capitalization, abbreviations, and codes are unchanged.

The Buildout's read

What the model surfaced from this award

Confidence: high

In plain English

Develop novel immunogenicity assays and sample collection technologies to assess COVID-19 vaccine effectiveness against variants.

Sub-sectors

vaccine-developmentcovid-19immunogenicity-assays

Why this matters

BARDA support for vaccine variant surveillance and assay innovation strengthens U.S. pandemic preparedness and vaccine development infrastructure.

Supply-chain signal

Signals demand for advanced diagnostic assay platforms, sample collection devices, and laboratory testing capabilities in pandemic response supply chains.

U.S.–China competition angle

Vaccine development and variant monitoring capabilities are strategically important for U.S. biotech leadership and pandemic response independence.

Generated by award_classification v2.0.0 via claude-haiku-4-5-20251001 on 2026-05-15. Cost: $0.002222.

Period of performance

Start

2023-09-29

End

2029-09-28

Status

activein 1230 days

Recipient

PPD DEVELOPMENT LP

UEI ZANENSW6C665

View full profile →

Sources

USAspending.gov — all awards for this UEI →
SAM.gov entity registration →
Award record ingested from usaspending. Source identifier CONT_AWD_75A50123C00045_7505_-NONE-_-NONE-.

The Buildout does not edit federal records. Any inaccuracy reflects the upstream source; it will update here when corrected there.